Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Medical Unit of ENT, Hearing and Balance, Karolinska University Hospital, Stockholm, Sweden.
JAMA Otolaryngol Head Neck Surg. 2023 May 1;149(5):390-396. doi: 10.1001/jamaoto.2023.0048.
Cholesteatoma in the middle ear is not regarded as a hereditary disease, but case reports of familial clustering exist in the literature, as well as observed familial cases in the clinical work. However, the knowledge regarding cholesteatoma as a hereditary disease is lacking in the literature.
To assess the risk of cholesteatoma in individuals with a first-degree relative surgically treated for the same disease.
DESIGN, SETTING, AND PARTICIPANTS: In this nested case-control study in the Swedish population between 1987 and 2018 of first-time cholesteatoma surgery identified from the Swedish National Patient Register, 2 controls per case were randomly selected from the population register through incidence density sampling, and all first-degree relatives for cases and controls were identified. Data were received in April 2022, and analyses were conducted between April and September 2022.
Cholesteatoma surgery in a first-degree relative.
The main outcome was first-time cholesteatoma surgery. The association between having a first-degree relative with cholesteatoma and the risk of cholesteatoma surgery in the index persons was estimated by odds ratios (ORs) and 95% CIs through conditional logistic regression analysis.
Between 1987 and 2018, 10 618 individuals with a first-time cholesteatoma surgery (mean [SD] age at surgery, 35.6 [21.5] years; 6302 [59.4%] men) were identified in the Swedish National Patient Register. The risk of having a cholesteatoma surgery was almost 4 times higher in individuals having a first-degree relative surgically treated for the disease (OR, 3.9; 95% CI, 3.1-4.8), but few cases were exposed overall. Among the 10 105 cases with at least 1 control included in the main analysis, 227 (2.2%) had at least 1 first-degree relative treated for cholesteatoma, while the corresponding numbers for controls were 118 of 19 553 control patients (0.6%). The association was stronger for individuals under the age of 20 years at first surgery (OR, 5.2; 95% CI, 3.6-7.6) and for a surgery involving the atticus and/or mastoid region (OR, 4.8; 95% CI, 3.4-6.2). There was no difference in the prevalence of having a partner with cholesteatoma between cases and controls (10 cases [0.3%] and 16 controls [0.3%]; OR, 0.92; 95% CI, 0.41-2.05), which implies that increased awareness does not explain the association.
In this Swedish case-control study using nationwide register data with high coverage and completeness, the findings suggest that the risk of cholesteatoma in the middle ear is strongly associated with a family history of the condition. Family history was nevertheless quite rare and can therefore only explain a limited number of all cases; these families could be an important source for information regarding the genetic background for cholesteatoma disease.
中耳胆脂瘤不被认为是一种遗传性疾病,但文献中已有家族聚集病例的报告,以及临床工作中观察到的家族病例。然而,关于胆脂瘤作为一种遗传性疾病的知识在文献中还很缺乏。
评估一级亲属因相同疾病接受手术治疗的个体患胆脂瘤的风险。
设计、地点和参与者:这是一项嵌套病例对照研究,在瑞典人群中,1987 年至 2018 年间,通过瑞典国家患者登记册确定首次胆脂瘤手术的病例,通过发病率密度抽样从人群登记册中随机选择每个病例的 2 名对照,所有病例和对照的一级亲属均被确定。数据于 2022 年 4 月收到,并于 2022 年 4 月至 9 月进行分析。
一级亲属的胆脂瘤手术。
主要结局是首次胆脂瘤手术。通过条件逻辑回归分析,估计有一级亲属患有胆脂瘤与索引个体患胆脂瘤手术风险之间的关联,使用比值比(OR)和 95%置信区间(CI)表示。
在 1987 年至 2018 年期间,瑞典国家患者登记册中确定了 10618 名首次接受胆脂瘤手术的个体(手术时的平均[SD]年龄,35.6[21.5]岁;6302[59.4%]为男性)。有一级亲属因该病接受手术治疗的个体患胆脂瘤的风险几乎高出 4 倍(OR,3.9;95%CI,3.1-4.8),但总体暴露病例较少。在主要分析中包括的 10105 名至少有 1 名对照的病例中,227 名(2.2%)有至少 1 名一级亲属因胆脂瘤接受治疗,而对照的相应数字为 19553 名对照患者中的 118 名(0.6%)。对于首次手术年龄在 20 岁以下的个体(OR,5.2;95%CI,3.6-7.6)和涉及鼓室和/或乳突区的手术(OR,4.8;95%CI,3.4-6.2),这种关联更强。病例和对照中患有伴发胆脂瘤的伴侣的患病率无差异(10 例[0.3%]和 16 例对照[0.3%];OR,0.92;95%CI,0.41-2.05),这意味着意识的提高并不能解释这种关联。
在这项使用具有高覆盖率和完整性的全国性登记数据的瑞典病例对照研究中,研究结果表明,中耳胆脂瘤的风险与该病的家族史密切相关。然而,家族史相当罕见,因此只能解释所有病例中的一小部分;这些家庭可能是了解胆脂瘤疾病遗传背景的重要信息来源。